Daiichi To Market New Hib Vaccine For Children In December
This article was originally published in PharmAsia News
Daiichi Sankyo plans to begin marketing a new hemophilus influenza type B vaccine for children in Japan beginning Dec. 19. The ActHIB drug was developed by Sanofi Pasteur of France. Japan accounts for 25 of the estimated 400,000 deaths globally from the disease that usually is caused by meningitis and pneumonia. The disease usually strikes children between the ages of four and 18 months of age, and about 500 are affected by it in Japan each year. (Click here for more
You may also be interested in...
Veklury is now the first US FDA-approved treatment for COVID-19, but its limited benefits means its lifespan as a blockbuster could be short.
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.